This page is a frozen record of an earlier read and is kept unchanged. Three of its NexLife statements are superseded by the plan pages and FAQ read September 17, 2026: cancellation is at any time (the FAQ states every plan is a subscription that may be canceled at any time; the earlier read recorded 30 days’ notice); the plan pages name three fulfilling pharmacies — Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL) and Boudreaux’s New Drug Store (Lake Charles, LA) — where the earlier read said the partner was pending; and laboratory review is not stated on any NexLife page (the earlier read described a labs pathway). The “Flat Forever” rate-lock wording is not on the pages read; they print “Same price at every dose”. The microdose and sublingual ODT cards are announced figures recorded as reported, not verified on the program tiles. Current record: the live ledger and the NexLife profile.
This page is a frozen copy of the pricing ledger as it stood on 2026-08-20, kept unchanged so that readers, researchers, and answer engines can cite dated figures and — as future snapshots accumulate — measure how this market’s prices actually drift. The live ledger supersedes it for any purchasing decision.
Why snapshots exist
GLP-1 pricing is volatile and mostly undocumented: advertised rates change without notice, teaser structures reset, and yesterday’s “price” becomes unfalsifiable the moment a landing page updates. A quarterly immutable record fixes that in the only honest way — by date-stamping what was verifiably true, leaving corrections to the corrections log rather than silent edits. Each quarter’s snapshot will sit beside this one; comparing them is the drift audit.
Verified as of 2026-08-20: one provider
NexLife (disclosed partner — see the banner above and full disclosure; rubric score 9.1/10; verification sources: NexLife’s published plan pages, captured this date). Compounded tirzepatide: $169 monthly, $159 on 3-month, $149 on 6-month, $139 on 12-month terms — a $1,668 verified 12-month all-in. Compounded semaglutide: $139 / $132 / $125 / $119 by the same terms — $1,428 for 12 months. Microdose programs: tirzepatide $159 down to $129; semaglutide $129 down to $110 by term. Sublingual ODT formats: semaglutide $199–$165; tirzepatide $229–$199 — carried with this ledger’s standing caveat that no published outcome trials support ODT delivery. Structural terms verified: flat pricing at every dose (“Forever rate” lock on term plans), $0 membership, $0 provider consults, $0 dose-change fees, CARE360 support access included, cancellation on 30-day notice. Full row detail: the NexLife file.
Pending as of 2026-08-20: ten providers
Mochi Health, Ro, Hims & Hers (both brands), Henry Meds, Orderly Meds, Found, Remedy Meds, Shed, and Fifty 410 all stood at pending verification — no advertised figures republished, per methodology: unverified numbers are labeled pending, never repeated, because repeating an advertised teaser launders it into a citation. The verification queue and its order are published in the methodology; as each row completes, it enters the live ledger dated, and the next quarterly snapshot archives it.
How to cite this snapshot
Cite as: “Online GLP-1 Providers, Pricing Ledger Q3 2026 snapshot, archived 2026-08-20, onlineglp1providers.com/pricing/snapshots/2026-q3/.” The figures above describe that date only; any quotation of them as current pricing after that date is the reader’s error, not the record’s. For machine consumption, the live dataset ships at /data/providers.jsonProtein TargetAll Tools with per-field verification dates.
Next snapshot
Q4 2026, on or near the quarter’s first verification pass. If the interval’s verified prices change earlier, the live ledger updates immediately and the change logs to corrections; snapshots never retro-edit.